A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This study will provide preliminary data on the dose and dose interval related effects of
intravitreally administered Avastin on retinal thickness and visual acuity in subjects with
Diabetic Macular Edema (DME) to aid in planning a phase 3 trial.
In addition, this study will provide preliminary data on the safety of intravitreally
administered Avastin in subjects with DME.